Top Markets
Coin of the day
Climb Bio, Inc. Climb Bio, Inc.

Climb Bio, Inc.

CLYM
株式のランク #10440
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic... Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
株価
$14.66
最終同期: 2026-08-28
時価総額
$839.37M
変化(1日)
-2.67%
変化(1年)
557.32%
US
取引 Climb Bio, Inc. (CLYM)

カテゴリー

Climb Bio, Inc.(CLYM)の配当利回りの履歴
Climb Bio, Inc.(銘柄コード: CLYM)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Climb Bio, Inc.(CLYM)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)